Results 311 to 320 of about 74,631 (338)
Some of the next articles are maybe not open access.
Determination of Purity of Levodopa and Levodopa Products by GLC
Journal of Pharmaceutical Sciences, 1974A simple GLC procedure for the detection and quanti-tation of possible impurities in levodopa raw material and commercial dosage forms is presented. The sample is reacted with N,O-bis(trimethylsilyl)acetamide in acetonitrile at ambient temperature for 30 min, and the silyl derivatives are separated on a methyl silicone column under isothermal ...
openaire +3 more sources
Neurology, 1996
Shortly after the introduction of high-dosage levodopa for the treatment of Parkinson's disease (PD), adverse motor effects of dyskinesias and clinical fluctuations ("wearing-off" and "on-off" phenomena) were seen [see [1] for historical review]. This soon led to the suggestion [2] that the introduction of levodopa for the treatment of PD should be ...
openaire +3 more sources
Shortly after the introduction of high-dosage levodopa for the treatment of Parkinson's disease (PD), adverse motor effects of dyskinesias and clinical fluctuations ("wearing-off" and "on-off" phenomena) were seen [see [1] for historical review]. This soon led to the suggestion [2] that the introduction of levodopa for the treatment of PD should be ...
openaire +3 more sources
Comparison of Levodopa with Carbidopa, and Levodopa with Domperidone in Parkinsonʼs Disease
Clinical Neuropharmacology, 1986In a comparison of the effects of domperidone and carbidopa during levodopa treatment, 20 patients with idiopathic Parkinson's disease were treated with fixed dose regimens of either levodopa 500 mg-domperidone 20 mg or levodopa 100 mg-carbidopa 25 mg; each for 8 weeks.
J D Parkes, P N Malcolm, N Langdon
openaire +3 more sources
Neurology, 1998
Whether a drug such as levodopa, which is prescribed for long periods, may be toxic is a legitimate and even indispensable question. The problem is no different from that posed by other drugs-such as calcium antagonists, antihypertensives, or hormones-normally prescribed for chronic diseases. What, however, is meant in this context by "toxic" (from the
openaire +3 more sources
Whether a drug such as levodopa, which is prescribed for long periods, may be toxic is a legitimate and even indispensable question. The problem is no different from that posed by other drugs-such as calcium antagonists, antihypertensives, or hormones-normally prescribed for chronic diseases. What, however, is meant in this context by "toxic" (from the
openaire +3 more sources
Pharmacokinetics and pharmacodynamics of levodopa
Movement Disorders, 2008The pharmacokinetics and pharmacodynamics of levodopa are dominated by two features: the short plasma half-life of the drug and the portion of the antiparkinsonian response that parallels the plasma levodopa levels, the so-called short-duration response. These features are the basis of motor fluctuations that complicate long-term therapy with levodopa.
openaire +3 more sources
The Lancet, 1970
Abstract Five patients with acute hepatic failure in coma or stupor were given drugs affecting neurotransmission. Levodopa (L-dopa) produced in three patients a striking though temporary improvement in the level of consciousness together with striking improvement in the previously abnormal electroencephalographic (E.E.G.) recordings.
J. D. Parkes +2 more
openaire +2 more sources
Abstract Five patients with acute hepatic failure in coma or stupor were given drugs affecting neurotransmission. Levodopa (L-dopa) produced in three patients a striking though temporary improvement in the level of consciousness together with striking improvement in the previously abnormal electroencephalographic (E.E.G.) recordings.
J. D. Parkes +2 more
openaire +2 more sources
JAMA: The Journal of the American Medical Association, 1975
To the Editor.— A variety of animal 1,2 and human 3 experiments have suggested that neural transmitters may mediate some of the symptoms of alcohol intoxication and withdrawal. Also, there is evidence to suggest that a dopamine agonist (apomorphine) reduces craving for alcohol in human alcoholics 4 and ethanol stimulation in mice.
openaire +2 more sources
To the Editor.— A variety of animal 1,2 and human 3 experiments have suggested that neural transmitters may mediate some of the symptoms of alcohol intoxication and withdrawal. Also, there is evidence to suggest that a dopamine agonist (apomorphine) reduces craving for alcohol in human alcoholics 4 and ethanol stimulation in mice.
openaire +2 more sources